New Analysis Shows Use of EXPAREL Associated with Improved Clinical and Economic Outcomes Following Hip Replacement Surgery
This retrospective analysis utilized data from the Premier Healthcare Database from
Results showed that patients undergoing THA who received EXPAREL compared to those who did not demonstrated a significant:
- Decrease in opioid consumption, expressed in oral morphine equivalent dosing (MED), among
Medicare and commercial insurance patients (105 mg MED and 81 mg MED reductions, respectively; P<0.0001) - Decrease in average hospital LOS by 0.7 days in both the Medicare and commercial insurance groups (P<0.0001)
- Decrease in total hospitalization costs in the Medicare population (–$561; P<0.0001)
- Increase in likelihood to be discharged home in both the
Medicare and commercial insurance groups (1.66 and 1.57, respectively; P<0.0001)
“When pain is not managed properly following total hip arthroplasty surgery, patients may experience an increase in hospital length of stay, opioid consumption and an overall delayed recovery,” said
Results of this study are consistent with findings from several retrospective studies and randomized controlled trials on the use of EXPAREL for total joint replacement procedures, including additional data from Dr. Asche, published last year in The
Between 2013 and 2015, an estimated one in five American adults reported a diagnosis of arthritis, the most common being osteoarthritis,2 which often requires THA. This procedure is growing steadily, with research estimating 572,000 annual THAs will be conducted in the U.S. by 2030.3
About
About EXPAREL®
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation. If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine. EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Warnings and Precautions Specific to EXPAREL: Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL. EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use. The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials. Warnings and Precautions for Bupivacaine-Containing Products: Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression. Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death. Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients. Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use. Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use. Full Prescribing Information is available at www.EXPAREL.com.
1
2 Barbour KE, Helmick CG, Boring M, et al. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation -
3 Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in
Company Contact:Pacira BioSciences, Inc. Susan Mesco , (973) 451-4030 Susan.Mesco@pacira.com Media Contact: Coyne Public RelationsAlyssa Schneider , (973) 588-2270 aschneider@coynepr.com
Source: Pacira BioSciences